Champions Oncology, Inc. (NASDAQ: CSBR)

$6.02 ▼ -0.25 (-3.99%)

As of May 13, 2026 04:00 PM

Sector: Healthcare Industry: Biotechnology CIK: 0000771856

Market Cap 84.43 Mn

P/E -35.76

P/S 1.46

Div. Yield 0.00

ROIC (Qtr) -0.01

Revenue Growth (1y) (Qtr) -2.82

Add ratio to table...

About

Champions Oncology, Inc. is a technology enabled research organization that creates solutions for drug discovery and development in the oncology sector. The company operates a research center that combines computational and experimental platforms to serve biopharmaceutical clients. At the heart of its offering is a proprietary bank of Patient Derived Xenograft models known as the TumorBank. This resource supports preclinical studies data licensing and software services. The firm aims to accelerate the identification and validation of cancer therapeutics...

Champions Oncology, Inc. is a technology enabled research organization that creates solutions for drug discovery and development in the oncology sector. The company operates a research center that combines computational and experimental platforms to serve biopharmaceutical clients. At the heart of its offering is a proprietary bank of Patient Derived Xenograft models known as the TumorBank. This resource supports preclinical studies data licensing and software services. The firm aims to accelerate the identification and validation of cancer therapeutics while reducing cost and time for its partners.

Champions Oncology generates revenue through four primary lines. First it sells research services that use its TumorBank and related platforms to run preclinical studies for pharmaceutical and biotechnology companies. Second it licenses access to its PDX model data and associated multi omic datasets. Third it offers a software as a service platform called Lumin Bioinformatics that provides analytics and artificial intelligence tools built on its Datacenter. Fourth it pursues internal drug discovery and development programs that may yield novel oncology therapeutics for future partnership or outlicensing. The research services business has historically been the largest contributor to total revenue.

The company operates through the following segments: Translational Oncology Solutions Research Services Data Licenses Software as a Service Business and Drug Discovery and Development.

• Translational Oncology Solutions (TOS) Business Research Services provides preclinical study contracts to pharmaceutical and biotechnology firms. The service uses the company’s TumorBank of Patient Derived Xenograft models to run in vivo and ex vivo experiments that measure drug response and resistance. Studies may include bioinformatics analysis to reveal genetic signatures linked to sensitivity or resistance. The segment also offers support for target identification patient selection combination strategy development and biomarker hypothesis generation. Work is conducted in both non regulatory and Good Clinical Regulatory Practice environments. Typical project fees range from one hundred twenty five thousand dollars to five hundred thousand dollars with a growing share in the higher band. The business has served approximately five hundred different clients over the past ten years and enjoys a high rate of repeat business across North America Europe and Asia.

• Data Licenses provide access to the company’s proprietary PDX model data and associated multi omic datasets. The licensed material includes genomics transcriptomics proteomics phosphoproteomics datasets clinical drug response measurements in vivo drug response readings and linked patient information. The Datacenter combines this internal data with approximately twenty thousand publicly available datasets to create a comprehensive oncology knowledge base. Customers obtain licenses to query the data for target discovery biomarker development and preclinical planning. Revenue from this line is generated through annual or multi year agreements based on data volume and access level.

• The Software as a Service Business centers on the Lumin Bioinformatics platform which is offered on an annual subscription basis. Lumin integrates the company’s Datacenter with analytics and artificial intelligence tools to support computational cancer research. Users can generate biomarker hypotheses uncover mechanisms of therapeutic resistance and guide further preclinical evaluation. The service is marketed to academic investigators pharmaceutical researchers and biotechnology scientists who seek to leverage the Datacenter for hypothesis generation and data driven decision making.

• The Drug Discovery and Development Business leverages the company’s computational and experimental platforms to identify and validate novel oncology therapeutics. The effort concentrates on three areas targeted therapy with drug conjugates immune oncology and cell therapy. Projects begin with Datacenter driven target identification followed by experimental validation using proprietary pharmacology and analytical platforms. Research and development teams are kept separate from the service divisions to protect intellectual property. The business maintains a pipeline of targets at various stages with some advancing toward therapeutic development. Commercialization options include partnership licensing or potential spin out transactions.

Champions Oncology occupies a niche position in the oncology research services market where it combines a large living TumorBank with deep molecular characterization and a proprietary software platform. The company competes with larger contract research organizations that offer generic preclinical testing but lack its specialized PDX resources. In the data licensing and SaaS spaces it faces competition from public genomic databases and various bioinformatics tools yet differentiates itself through the longitudinal living nature of its model bank and its integrated analytics. In the drug discovery arena it contends with established biopharmaceutical firms but leverages its internal discovery engine to generate early stage assets that may attract partnership interest. Competitive advantages include the scale and depth of the TumorBank the richness of the Datacenter the ability to move seamlessly from data insight to experimental validation and a focused expertise in oncology specific models.

The company serves a diverse group of clients primarily consisting of pharmaceutical and biotechnology enterprises that seek preclinical testing data licenses or computational tools for oncology drug development. It also works with academic research institutions and nonprofit organizations that use its SaaS platform and data licenses for basic and translational science. While the filing does not disclose individual customer names it notes a broad geographic reach across North America Europe and Asia and a high rate of repeat business among its core pharma and biotech clients.

Investment thesis

Bull case

The company’s core translational oncology services (TOS) platform continues to be a strong, differentiated asset that commands premium pricing from large pharmaceutical clients. With a multi‑omic patient‑derived xenograft (PDX) bank that is one of the deepest in the industry, Champions can provide high‑value preclinical data that is difficult to replicate. This platform not only supports current service revenue but also creates a low‑cost, high‑margin pipeline of repeat work, as evidenced by the reported decline in customer cancellations and increased bookings‑to‑revenue conversion. The sustained demand from major biotech and pharma customers indicates a robust tailwind for top‑line growth even in a tightening budget environment.
A significant hidden catalyst lies in the emerging data licensing business, which has already delivered revenue for three consecutive quarters since its first license deal. The data platform leverages the same proprietary PDX bank used in the TOS business, creating a cross‑sell opportunity that can unlock additional value without proportionate incremental cost. While management remains deliberately vague about the total addressable market, the consistent quarterly revenue generation and the growing interest from AI and machine learning‑driven drug discovery firms suggest a scalable, high‑margin business that could become a major driver of profitability as it matures. Investors often overlook the potential of data monetization in life sciences, and this represents an under‑priced growth engine.
The radiopharmaceutical services expansion represents another structural shift that is expected to improve gross margins. By moving radio‑labeling and radiochemistry in‑house, Champions will cut outsourcing costs that have eroded margins to 43% this quarter from 50% last year. The new infrastructure, coupled with over 30 in‑vivo PDX models, positions the company to offer end‑to‑end biodistribution and efficacy studies—a service set that is in high demand for targeted therapies and radioligand therapies. As the radiopharma market expands, the company can command premium pricing and achieve margin recovery, turning a current expense center into a revenue‑generating asset.
The company’s balance sheet remains healthy, with $10.3 million in cash, zero debt, and a positive operating cash flow of $0.6 million. This liquidity cushion allows the firm to continue investing in R&D, sales and marketing, and new infrastructure without external borrowing, preserving shareholder value and providing a buffer against cyclical downturns. The cash neutrality in the second quarter and projected cash growth in the second half of the fiscal year indicate disciplined capital allocation and the ability to fund upcoming growth initiatives, including the scaling of the data business and potential partnership or equity investments in Corellia. A debt‑free, cash‑positive position also enhances flexibility for strategic acquisitions or expansion into new therapeutic areas.
Management’s focus on a disciplined investment in the data business and radiopharmaceutical platform reflects a clear long‑term strategic vision. The incremental $0.6 million increase in R&D spend and the deliberate scaling of sales and marketing for data licensing demonstrate targeted execution rather than opportunistic burn. These investments are expected to pay off in the near term through larger, more durable bookings, and in the long term by establishing Champions as a comprehensive preclinical partner that can capture a larger share of the drug development lifecycle. Such a shift aligns with industry trends toward integrated, data‑rich research services, positioning the company well for future competitive advantage.

The company’s core translational oncology services (TOS) platform continues to be a strong, differentiated asset that commands premium pricing from large pharmaceutical clients. With a multi‑omic patient‑derived xenograft (PDX) bank that is one of the deepest in the industry, Champions can provide high‑value preclinical data that is difficult to replicate. This platform not only supports current service revenue but also creates a low‑cost, high‑margin pipeline of repeat work, as evidenced by the reported decline in customer cancellations and increased bookings‑to‑revenue conversion. The sustained demand from major biotech and pharma customers indicates a robust tailwind for top‑line growth even in a tightening budget environment.
A significant hidden catalyst lies in the emerging data licensing business, which has already delivered revenue for three consecutive quarters since its first license deal. The data platform leverages the same proprietary PDX bank used in the TOS business, creating a cross‑sell opportunity that can unlock additional value without proportionate incremental cost. While management remains deliberately vague about the total addressable market, the consistent quarterly revenue generation and the growing interest from AI and machine learning‑driven drug discovery firms suggest a scalable, high‑margin business that could become a major driver of profitability as it matures. Investors often overlook the potential of data monetization in life sciences, and this represents an under‑priced growth engine.
The radiopharmaceutical services expansion represents another structural shift that is expected to improve gross margins. By moving radio‑labeling and radiochemistry in‑house, Champions will cut outsourcing costs that have eroded margins to 43% this quarter from 50% last year. The new infrastructure, coupled with over 30 in‑vivo PDX models, positions the company to offer end‑to‑end biodistribution and efficacy studies—a service set that is in high demand for targeted therapies and radioligand therapies. As the radiopharma market expands, the company can command premium pricing and achieve margin recovery, turning a current expense center into a revenue‑generating asset.
The company’s balance sheet remains healthy, with $10.3 million in cash, zero debt, and a positive operating cash flow of $0.6 million. This liquidity cushion allows the firm to continue investing in R&D, sales and marketing, and new infrastructure without external borrowing, preserving shareholder value and providing a buffer against cyclical downturns. The cash neutrality in the second quarter and projected cash growth in the second half of the fiscal year indicate disciplined capital allocation and the ability to fund upcoming growth initiatives, including the scaling of the data business and potential partnership or equity investments in Corellia. A debt‑free, cash‑positive position also enhances flexibility for strategic acquisitions or expansion into new therapeutic areas.
Management’s focus on a disciplined investment in the data business and radiopharmaceutical platform reflects a clear long‑term strategic vision. The incremental $0.6 million increase in R&D spend and the deliberate scaling of sales and marketing for data licensing demonstrate targeted execution rather than opportunistic burn. These investments are expected to pay off in the near term through larger, more durable bookings, and in the long term by establishing Champions as a comprehensive preclinical partner that can capture a larger share of the drug development lifecycle. Such a shift aligns with industry trends toward integrated, data‑rich research services, positioning the company well for future competitive advantage.

Bear case

Revenue growth remains flat at $14 million versus the same period last year, and the company’s adjusted EBITDA slipped from $2 million a year ago to a modest $60,000 this quarter. While the operating loss of $0.5 million is largely driven by non‑cash expenses, it signals that the company is not yet generating sustainable profit from its core services. Investors should be cautious, as flat top‑line growth combined with declining margins suggests that the firm is still in a rebuilding phase rather than a strong expansion mode.
The gross margin contraction from 50% to 43% is primarily attributed to higher outsourced lab costs for radio‑labeling, a cost that management has not fully explained. The reliance on external vendors for critical services introduces price volatility and potential quality risk that could erode future margin improvements. Even with an in‑house shift planned, the capital expenditure required to build radiochemistry infrastructure and the time lag before cost savings materialize may delay the expected margin rebound, creating a cash flow challenge.
Management’s evasive answers during the Q&A reveal uncertainty around key growth engines. CEO Brainin repeatedly avoided specifying the size of the data licensing opportunity and the revenue trajectory, responding with phrases such as “no changes” and “wish I knew.” This lack of transparency casts doubt on the scalability of the data business, and suggests that the company has not yet quantified the revenue potential or established a clear go‑to‑market strategy. Investors may be wary of a company that cannot articulate the value proposition or execution plan for its most promising growth segment.
The Corellia subsidiary, while positioned as a potential catalyst, remains underfunded and heavily reliant on external investment. CEO Brainin acknowledged the need for additional capital but did not provide a concrete plan for raising funds or a clear milestone framework for partnership deals. The absence of a defined funding strategy raises concerns about the subsidiary’s ability to advance its drug discovery pipeline, particularly in an environment where venture capital is tightening and biotech funding is constrained. If Corellia fails to secure necessary capital, it could become a sunk cost rather than a value‑add, weakening the overall business model.
The company’s cash position, while debt‑free, is modest at just over $10 million, which is a narrow buffer given the ongoing investments in R&D, sales, and infrastructure. Operating cash flow is only $0.6 million, and the firm anticipates cash neutrality in the second quarter. This limited runway forces the company to depend heavily on incremental revenue or new capital raises to fund growth, increasing financial risk. Should customer budget constraints persist or the market for radiopharmaceutical services prove slower than expected, the firm could face liquidity constraints that threaten its ability to sustain operations or invest in high‑potential projects.

Revenue growth remains flat at $14 million versus the same period last year, and the company’s adjusted EBITDA slipped from $2 million a year ago to a modest $60,000 this quarter. While the operating loss of $0.5 million is largely driven by non‑cash expenses, it signals that the company is not yet generating sustainable profit from its core services. Investors should be cautious, as flat top‑line growth combined with declining margins suggests that the firm is still in a rebuilding phase rather than a strong expansion mode.
The gross margin contraction from 50% to 43% is primarily attributed to higher outsourced lab costs for radio‑labeling, a cost that management has not fully explained. The reliance on external vendors for critical services introduces price volatility and potential quality risk that could erode future margin improvements. Even with an in‑house shift planned, the capital expenditure required to build radiochemistry infrastructure and the time lag before cost savings materialize may delay the expected margin rebound, creating a cash flow challenge.
Management’s evasive answers during the Q&A reveal uncertainty around key growth engines. CEO Brainin repeatedly avoided specifying the size of the data licensing opportunity and the revenue trajectory, responding with phrases such as “no changes” and “wish I knew.” This lack of transparency casts doubt on the scalability of the data business, and suggests that the company has not yet quantified the revenue potential or established a clear go‑to‑market strategy. Investors may be wary of a company that cannot articulate the value proposition or execution plan for its most promising growth segment.
The Corellia subsidiary, while positioned as a potential catalyst, remains underfunded and heavily reliant on external investment. CEO Brainin acknowledged the need for additional capital but did not provide a concrete plan for raising funds or a clear milestone framework for partnership deals. The absence of a defined funding strategy raises concerns about the subsidiary’s ability to advance its drug discovery pipeline, particularly in an environment where venture capital is tightening and biotech funding is constrained. If Corellia fails to secure necessary capital, it could become a sunk cost rather than a value‑add, weakening the overall business model.
The company’s cash position, while debt‑free, is modest at just over $10 million, which is a narrow buffer given the ongoing investments in R&D, sales, and infrastructure. Operating cash flow is only $0.6 million, and the firm anticipates cash neutrality in the second quarter. This limited runway forces the company to depend heavily on incremental revenue or new capital raises to fund growth, increasing financial risk. Should customer budget constraints persist or the market for radiopharmaceutical services prove slower than expected, the firm could face liquidity constraints that threaten its ability to sustain operations or invest in high‑potential projects.

Product and Service Breakdown of Revenue (2025)

Peer comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	QNTM	Quantum Biopharma Ltd.	925,748.71 Bn	0.68	-	-
2	LEGN	Legend Biotech Corp	2,886.00 Bn	-4.05	2,805.37	0.32 Bn
3	EVAX	Evaxion A/S	1,751.45 Bn	0.00	47.33	-
4	VRTX	Vertex Pharmaceuticals Inc / Ma	115.93 Bn	29.31	9.66	-
5	REGN	Regeneron Pharmaceuticals, Inc.	74.80 Bn	16.90	5.01	1.99 Bn
6	ALNY	Alnylam Pharmaceuticals, Inc.	38.74 Bn	76.91	9.04	-
7	RVMD	Revolution Medicines, Inc.	28.52 Bn	-25.25	-	-
8	BNTX	BioNTech SE	27.82 Bn	-19.84	15.02	0.41 Bn

Research Tools